Privo is excited to work closely with its collaborators at the FDA, the NCI and the NIDCR.
Support from the FDA, NCI, and NIDCR validates the scientific merit and potential impact of our PRV platform technology. These partnerships reflect confidence in our approach to cancer treatment.
Nondilutive funding enables us to accelerate product development and clinical trials without diluting shareholder value, allowing us to bring treatments to patients faster.
Working closely with leading federal health institutions provides invaluable guidance and resources, enhancing our research capabilities and regulatory pathway.